Cargando…
Extracorporeal Photopheresis—An Overview
Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of cutaneous T-cell lymphoma (CTCL) in 1988. After the first positive experiences with CTCL, additional indications have been su...
Autores principales: | Cho, Ara, Jantschitsch, Christian, Knobler, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119964/ https://www.ncbi.nlm.nih.gov/pubmed/30211164 http://dx.doi.org/10.3389/fmed.2018.00236 |
Ejemplares similares
-
Guidelines on the use of extracorporeal photopheresis
por: Knobler, R, et al.
Publicado: (2014) -
European dermatology forum – updated guidelines on the use of extracorporeal photopheresis 2020 – part 1
por: Knobler, R., et al.
Publicado: (2020) -
European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2
por: Knobler, R., et al.
Publicado: (2020) -
Extracorporeal photopheresis: Review of technical aspects
por: Arora, Satyam, et al.
Publicado: (2017) -
Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
por: Bojanic, Ines, et al.
Publicado: (2023)